RYR2 and cardiac arrhythmia: In vivo gene delivery of this recombinant CaM into the heart partially restored RyR2 refractoriness and decrease a chance of arrhythmias in the catecholaminergic polymorphic ventricular tachycardia (CPVT) model caused by calsequestrin mutation (Liu et al., 2018).